MX337721B - Compuestos de heteroarilo como ligandos del receptor 5-ht4. - Google Patents

Compuestos de heteroarilo como ligandos del receptor 5-ht4.

Info

Publication number
MX337721B
MX337721B MX2013014577A MX2013014577A MX337721B MX 337721 B MX337721 B MX 337721B MX 2013014577 A MX2013014577 A MX 2013014577A MX 2013014577 A MX2013014577 A MX 2013014577A MX 337721 B MX337721 B MX 337721B
Authority
MX
Mexico
Prior art keywords
receptor ligands
heteroaryl compounds
compounds
formula
pharmaceutically acceptable
Prior art date
Application number
MX2013014577A
Other languages
English (en)
Other versions
MX2013014577A (es
Inventor
Venkateswarlu Jasti
Ramakrishna Nirogi
Gopinadh Bhyrapuneni
Abdul Rasheed Mohammed
Anil Karbhari Shinde
Jyothsna Ravula
Sriramachandra Murthy Patnala
Ramasastri Kambhampati
Suresh Yarlagadda
Srinivasa Rao Ravella
Praveen Kumar Roayapalley
Pradeep Jayarajan
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2013014577A publication Critical patent/MX2013014577A/es
Publication of MX337721B publication Critical patent/MX337721B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Structures Or Materials For Encapsulating Or Coating Semiconductor Devices Or Solid State Devices (AREA)
  • Semiconductor Integrated Circuits (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se relaciona con compuestos novedosos de fórmula (I) y sus sales farmacéuticamente aceptables, y con composiciones que los contienen. (Ver Formula) La presente invención también se relaciona con un proceso para la preparación de los compuestos novedosos mencionados y de sus sales farmacéuticamente aceptables. Los compuestos de fórmula (I) son útiles en el tratamiento de diversos trastornos relacionados con los receptores 5-HT4.
MX2013014577A 2011-09-19 2012-01-05 Compuestos de heteroarilo como ligandos del receptor 5-ht4. MX337721B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3203CH2011 2011-09-19
PCT/IN2012/000011 WO2013042135A1 (en) 2011-09-19 2012-01-05 Heteroaryl compounds as 5-ht4 receptor ligands

Publications (2)

Publication Number Publication Date
MX2013014577A MX2013014577A (es) 2014-03-31
MX337721B true MX337721B (es) 2016-03-16

Family

ID=46001349

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014577A MX337721B (es) 2011-09-19 2012-01-05 Compuestos de heteroarilo como ligandos del receptor 5-ht4.

Country Status (26)

Country Link
US (2) US9079894B2 (es)
EP (1) EP2758394B1 (es)
JP (1) JP5714729B2 (es)
KR (1) KR101551481B1 (es)
CN (1) CN103380131B (es)
AP (1) AP3307A (es)
AU (1) AU2012311057B2 (es)
BR (1) BR112014001083B8 (es)
CA (1) CA2823548C (es)
CY (1) CY1116173T1 (es)
DK (1) DK2758394T3 (es)
EA (1) EA022374B1 (es)
ES (1) ES2531885T3 (es)
HK (1) HK1187340A1 (es)
HR (1) HRP20150229T1 (es)
IL (1) IL231305A0 (es)
ME (1) ME02107B (es)
MX (1) MX337721B (es)
PL (1) PL2758394T3 (es)
PT (1) PT2758394E (es)
RS (1) RS53940B1 (es)
SG (1) SG2014003560A (es)
SI (1) SI2758394T1 (es)
SM (1) SMT201500087B (es)
WO (1) WO2013042135A1 (es)
ZA (1) ZA201309100B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140057895A1 (en) * 2011-06-07 2014-02-27 Kazuhiro Mizuno Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof
CN105120851A (zh) * 2013-04-05 2015-12-02 Abc生物科学公司 用于医疗用途，具体为用于治疗与氧化应激相关的疾病或者炎症和用于保存或者洗涤器官的barettin及其衍生物
EP3099675B1 (en) * 2013-12-16 2018-02-14 Suven Life Sciences Limited Indazole compounds as 5-ht4 receptor agonists
AU2014404001B2 (en) * 2014-08-16 2017-12-14 Suven Life Sciences Limited Process for large scale production of 1-isopropyl-3-{5- [1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}- 1h-indazole oxalate
SI3265459T1 (sl) 2015-02-13 2019-09-30 Suven Life Sciences Limited, Amidne spojine kot 5-HT4 receptor agonisti
CN107540568A (zh) * 2017-08-25 2018-01-05 许昌恒生制药有限公司 一种乙氧酰胺苯甲酯的制备方法
MA53918A (fr) 2018-10-18 2022-01-26 Suven Life Sciences Ltd Nouvelles utilisations d'un agoniste du récepteur 5-ht4
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN110746450A (zh) * 2019-09-17 2020-02-04 济南康和医药科技有限公司 一种贝前列素钠关键中间体的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492919A (en) * 1991-08-03 1996-02-20 Smithkline Beecham P.L.C. 5-HT4 receptor antagonists
TW360653B (en) * 1995-03-01 1999-06-11 Janssen Pharmaceutica Nv A oxadiazole compound having colon motility stimulating properties, its preparation process and its pharmaceutical composition
AU707325B2 (en) * 1995-11-09 1999-07-08 Sanofi-Aventis 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one derivatives for use as 5-HT4 or H3 receptor ligands
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
ATE461192T1 (de) 2003-11-24 2010-04-15 Pfizer Chinoloncarbonsäureverbindungen mit 5-ht4- rezeptoragonistischer wirkung
GEP20094727B (en) * 2005-02-22 2009-07-10 Pfizer Oxyindole derivatives as 5ht4 receptor agonists
US8816090B2 (en) 2005-02-25 2014-08-26 Pfizer Inc. Benzisoxazole derivatives
ES2333545T3 (es) 2005-07-22 2010-02-23 Pfizer, Inc. Derivados de indazolcarboxamida como agonistas de receptores 5ht4.
AU2006328602B2 (en) * 2005-12-23 2012-05-31 F. Hoffmann-La Roche Ag Aryl-isoxazolo-4-yl-oxadiazole derivatives
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
EP2406255B1 (en) * 2009-03-09 2015-04-29 Glaxo Group Limited 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases

Also Published As

Publication number Publication date
MX2013014577A (es) 2014-03-31
WO2013042135A8 (en) 2013-08-15
EA201391056A1 (ru) 2013-12-30
HK1187340A1 (zh) 2014-04-04
ZA201309100B (en) 2014-08-27
SG2014003560A (en) 2014-11-27
IL231305A0 (en) 2014-04-30
CA2823548C (en) 2015-10-27
BR112014001083B8 (pt) 2022-06-14
US20150283125A1 (en) 2015-10-08
US9079894B2 (en) 2015-07-14
AU2012311057B2 (en) 2015-09-17
EP2758394A1 (en) 2014-07-30
BR112014001083B1 (pt) 2022-02-01
US9636335B2 (en) 2017-05-02
PL2758394T3 (pl) 2015-08-31
CN103380131B (zh) 2015-12-02
KR20130109228A (ko) 2013-10-07
CN103380131A (zh) 2013-10-30
CY1116173T1 (el) 2017-02-08
AU2012311057A1 (en) 2013-08-01
AP2013007301A0 (en) 2013-12-31
NZ619776A (en) 2015-04-24
ME02107B (me) 2015-10-20
ES2531885T3 (es) 2015-03-20
DK2758394T3 (en) 2015-04-20
SI2758394T1 (sl) 2015-05-29
AP3307A (en) 2015-06-30
PT2758394E (pt) 2015-04-22
RS53940B1 (en) 2015-08-31
CA2823548A1 (en) 2013-03-28
WO2013042135A1 (en) 2013-03-28
EA022374B1 (ru) 2015-12-30
HRP20150229T1 (hr) 2015-04-10
EP2758394B1 (en) 2015-02-18
JP5714729B2 (ja) 2015-05-07
BR112014001083A2 (pt) 2019-10-01
BR112014001083A8 (pt) 2021-08-24
SMT201500087B (it) 2015-05-05
JP2014509320A (ja) 2014-04-17
KR101551481B1 (ko) 2015-09-08
US20140187581A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
MX2013014577A (es) Compuestos de heteroarilo como ligandos del receptor 5-ht4.
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
MX339858B (es) Compuestos novedosos como ligandos del receptor h3 de la histamina.
PH12015500376A1 (en) Novel bicyclic pyridinones
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MX2013013950A (es) Derivados de riperidina 3-espirociclicos como antagonistas de los receptores de grelina.
EA201400064A1 (ru) Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
MX360330B (es) Regimen de administracion para nitrocatecoles.
MX2012002608A (es) Compuesto 1,2-dihidro -2-oxoquinolona como ligandos del receptor 5ht4.
MX362858B (es) Proceso para la preparacion de pemetrexed y sal de lisina del mismo.
MX2013003202A (es) Inhibidores de oxadiazol de la produccion de leucotrienos.
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
MX2012007783A (es) Compuestos sulfona que actuan como ligandos del receptor 5-ht6.
EA201390327A1 (ru) Гетероциклильные соединения в качестве лигандов гистаминовых hрецепторов
WO2013048949A3 (en) Selective nr2b antagonists
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
MX337106B (es) Antagonistas no competitivos de receptores nicotinicos.
EA201590413A1 (ru) Соединения акриламида в качестве лигандов h-рецептора гистамина
MX2014000855A (es) Moduladores receptores de glucagon de quinolinilo.
MX364929B (es) Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4.
TN2013000441A1 (en) 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
MX2013007952A (es) Antagonistas no competitivos de receptores nicotinicos.
TN2013000122A1 (en) Oxadiazole inhibitors of leukotriene production
UA108500C2 (ru) Неконкурентные антагонисты никотиновых рецепторов

Legal Events

Date Code Title Description
FG Grant or registration